U.K.’s NICE Plans Office To Help Drugs Gain Coverage Faster
Executive Summary
NICE is responding to a government consultation on how the cost-effectiveness watchdog should update its methodologies and processes in evaluating new products by opening a new Office for Market Access, which it says will help life sciences companies prepare for its appraisals and better their chances for coverage.
You may also be interested in...
Ebola Threat Prompts EU To Focus On Adaptive Licensing
The spread of Ebola to Europe is prompting regulators and industry to explore in more detail adaptive licensing pathways to speed access to potentially life-saving drugs.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.